Saturday 17 October 2026
Export OCS’s income statement to Excel — free account
Oculis Holding AG
Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.
7.29
0.11
−1.49%
Follow OCS
Oculis Holding AG (OCS) P/E ratio
Oculis Holding AG has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 109× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 108× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 109×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RGNX REGENXBIO Inc. compare | n/m |
| ALT Altimmune, Inc. compare | n/m |
| OCS Oculis Holding AG | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | n/m |
| ARVN Arvinas, Inc. compare | 53.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)